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Background: The incidence of acute rejection and the morbidity of systemic
cyclosporine (INN: ciclosporin) after lung transplantation is significant.
Experimental evidence suggests that the allograft locally modulates the
immune mechanisms of acute rejection. The purpose of this study was to
determine whether aerosolized cyclosporine would prevent acute cellular
rejection, achieve effective graft concentrations with low systemic drug
delivery, and locally affect production of the inflammatory cytokines
involved in acute rejection. Methods: Unilateral orthotopic left lung trans-
plantation was performed in 64 rats (ACI to Lewis), which were divided into
eight groups (each group, n 5 8): group A, no treatment; groups B to D,
aerosol cyclosporine 1 to 3 mg/kg per day, respectively; groups E to H,
systemic cyclosporine 2, 5, 10, and 15 mg/kg per day, respectively. After the
animals were killed on postoperative day 2, 4, or 6, the transplanted lung,
native lung, spleen, and blood were collected. Histologic studies, high-
pressure liquid chromatography for trough cyclosporine concentrations,
and reverse-transcriptase polymerase chain reaction for cytokine gene
expression were performed. Results: Untreated animals showed grade 4
rejection by postoperative day 6. Aerosol cyclosporine prevented acute
rejection in a dose-dependent fashion, with group D animals (3 mg/kg per
day) showing minimal grade 1 changes. Among animals receiving systemic
cyclosporine, only group H (15 mg/kg per day) controlled (grade 1)
rejection. However, aerosol cyclosporine, at an 80% lower dose, achieved
significantly lower concentrations of cyclosporine in the graft (12,349 vs
28,714 ng/mg, p 5 0.002004) and blood (725 vs 3306 ng/ml, p 5 0.000378).
Group F (systemic 5 mg/kg per day) had higher cyclosporine concentrations
in the blood than group D (p 5 0.004572) and similar tissue concentrations
(p 5 0.115180), yet had grade 2 rejection. Reverse-transcriptase polymerase
chain reaction demonstrated equivalent suppression of inducible nitric
oxide synthase but a 20- to 25-fold higher expression of interleukin-6,
interleukin-10, and interferon-g in group D versus group H recipient
allografts. Conclusion: Local delivery of cyclosporine by aerosol inhalation
dose-dependently prevented acute pulmonary allograft rejection. Effective
graft levels and low systemic drug delivery required significantly lower
doses than systemic therapy alone. The gene expression of proinflammatory
cytokines involved in allograft rejection was suppressed by aerosol cyclo-
sporine therapy. (J Thorac Cardiovasc Surg 1998;115:28-37)
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Pulmonary transplantation is an accepted andestablished therapeutic option for a variety of
end-stage lung diseases.1 Despite the initiation of
systemic immunosuppression with cyclosporine
(INN: ciclosporin) or tacrolimus-based triple drug
therapy shortly after implantation, acute cellular
rejection occurs frequently, with an incidence ap-
proaching 90% in our transplant population.2 In-
creasing evidence suggests that the acute rejection
process is initiated and modulated locally within the
allograft. Alloactivation by major histocompatibility
complex (MHC) antigens on passenger leukocytes
in the graft provokes an intense inflammatory reac-
tion resulting in a rapid influx of neutrophils and
macrophages. The subsequent release of cytokines
and nitric oxide promotes local macrophage ampli-
fication and donor-specific T- and B-cell clonal
expansion.
Episodes of acute cellular rejection are usually
managed with pulse corticosteroids or cytolytic ther-
apy. These efforts are not uniformly successful, and
persistent acute rejection develops in many recipi-
ents.3 Aside from the inflammatory reaction causing
pulmonary tissue damage, the two major sequelae of
acute rejection are the limiting factors to successful
lung transplantation today. First, the end-organ
toxicity from continued systemic immunosuppres-
sion is well recognized. The incidence of infections,
nephrotoxicity, diabetes, hypertension, and solid
organ tumors is significant in the transplant popu-
lation.4 Second, acute rejection may be the predom-
inant risk factor for the development of obliterative
bronchiolitis.5
It is presumed that systemic immunosuppression
incurs a delay in achieving appropriate allograft
drug levels, thereby permitting the local inflamma-
tory response to begin. It is conceivable, therefore,
that acute rejection could be prevented if the acti-
vation of antigen-presenting cells and the matura-
tion and proliferation of effector cells was arrested
by the early administration of immunosuppressive
agents directly into the allograft. Aerosol cyclospor-
ine represents an alternative drug delivery system
that may be ideal in achieving this goal.
Regional immunosuppression is predicated on
two basic concepts. First, controlling the early intra-
graft immune events will prevent acute rejection.
Second, obtaining high local drug delivery with low
systemic drug delivery will diminish the adverse
consequences of systemic immunosuppression. Lo-
cal cyclosporine, tacrolimus, and steroid therapy
have been used in numerous experimental models of
heart, liver, and kidney6-9 transplantation. These
studies have reported promising results in control-
ling rejection and achieving low systemic drug deliv-
ery. However, many of these models have used drug
delivery systems that make widespread clinical ap-
plication unlikely. Lung transplantation offers a
unique opportunity to study the efficacy of local
immunosuppression because of the ease with which
airborne drugs may be deposited in the allograft by
inhalation. Our group has previously demonstrated
the efficacy of aerosol cyclosporine in canine10 and
rodent11, 12 models with a variety of aerosol and
systemic cyclosporine doses. Recent modification of
an efficient and commercially available aerosol de-
livery system, new data altering the calculated in-
trapulmonary deposition of cyclosporine, and the
widespread availability of molecular techniques
have prompted us to explore the applicability of
aerosol cyclosporine in controlling acute rejection in
a rodent lung transplant model. The objective of this
experiment was to determine whether aerosol cyclo-
sporine as locoregional monotherapy would prevent
acute cellular rejection, achieve effective allograft
and low systemic drug delivery, and locally attenuate
the inflammatory cytokines associated with acute
rejection.
Materials and methods
Animals. ACI and Lewis rats, 4 to 8 weeks old, were
purchased from Harlan Sprague Dawley (Indianapolis,
Ind.). The animals were housed in a specific pathogen-
free facility at the University of Pittsburgh Bioscience
Tower. All animals received humane care in compliance
with the “Principles of Laboratory Animal Care” formu-
lated by the National Society for Medical Research and
the “Guide for the Care and Use of Laboratory Animals”
prepared by the National Academy of Sciences and pub-
lished by the National Institutes of Health (NIH Publica-
tion No. 86-23, revised 1985).
Lung transplantation. Unilateral orthotopic left lung
transplantation across MHC and minor antigen disparate
species13 was performed with ACI rats used as donors and
Lewis rats, weighing 225 to 275 gm, as recipients. Allo-
grafts were transplanted by the cuff technique as previ-
ously described.12, 14 Graft cold ischemic time in 40° C
heparinized lactated Ringer’s solution ranged from 20 to
40 minutes. No antibiotic prophylaxis was administered
after the operation.
Experimental groups and specimen collection. Recipi-
ents were divided into eight experimental groups. Group
A (n 5 8) animals served as controls and received no
immunosuppression. Group B, C, and D animals (each
group, n 5 8) received aerosol cyclosporine in dosages of
1, 2, and 3 mg/kg per day, respectively. Group E, F, G, and
H animals (each group, n 5 8) received systemic cyclo-
sporine/polyoxyl castor oil (Cremophore) dissolved in
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saline solution by subcutaneous injection in dosages of 2,
5, 10, and 15 mg/kg per day, respectively. All animals
received the first assigned cyclosporine dose within 1 hour
of transplantation on postoperative day (POD) 0. The
same dose was dispensed every 24 hours until the animal
was killed on POD 2, 4, or 6. The last cyclosporine dose
was administered 24 hours before the animal was put to
death, and the specimens were harvested immediately
thereafter. All recipients were killed by inhalation of
methoxyflurane, followed by exsanguination via direct
cardiac puncture. Whole blood was collected in ethyl-
enediaminetetraacetic acid Vacutainer 2.5 ml tubes (Bec-
ton Dickinson, Franklin Lakes, N.J.). The allograft, native
lung, and spleen were cryopreserved by immersion in
liquid nitrogen after placement in 1.7 ml sterile microcen-
trifuge tubes (VWR Scientific, Bridgeport, N.J.).
Aerosol generation. Cyclosporine powder (a generous
gift from Sandoz Pharmaceuticals Inc., Basel, Switzer-
land) was dissolved in 100% ethanol to a final concentra-
tion of 40 mg/ml. The cyclosporine/ethanol solution was
delivered to the commercially available Aero-Tech II
Nebulizer (CIS-US, Inc., Bedford, Mass.) at a rate of 1
ml/min. A compressed-air driving pressure of 80 psi with
entrained room air resulted in a chamber flow rate of 13.9
L/min, generating an aerosol mist with a mass median
aerodynamic equivalent of 0.7 to 1.2 mm in diameter with
a geometric standard deviation of 1.6 mm. The aerosol
exposure chamber (Lovelace Inhalation and Toxicology
Research Institute [ITRI], Albuquerque, N.M.) is a 24-
port laminar flow chamber with individual nosepieces that
allows simultaneous exposure to multiple animals.
The airborne concentration of cyclosporine in the
chamber was determined by continuously drawing air
samples at a rate of 0.534 L/min onto 47 mm 0.5 mm
polytetrafluoroethylene filters (Millipore, Bedford,
Mass.). Gravimetric analysis was conducted on the filter
sample to determine the amount (in milligrams) of depos-
ited cyclosporine. The time necessary per exposure to
achieve the desired intrapulmonary deposition of cyclo-
sporine was calculated on the basis of a modification of
the Alarie formula.15 The chamber-air concentration of
cyclosporine in milligrams per liter (amount of deposited
cyclosporine per filter in milligrams 4 0.534 L/min 3
number of minutes per sampling) 3 0.25 L/min (rat
minute ventilation) 3 0.1 (10% 5 efficiency of deposi-
tion)16 (personal communication from ITRI) yielded the
anticipated intrapulmonary deposition of cyclosporine in
milligrams per minute. The animal’s weight (in kilograms)
times the desired dose (in milligrams per kilogram per
day) divided by the intrapulmonary deposition (in milli-
grams per minute) yielded the number of minutes neces-
sary to achieve the desired dose of cyclosporine by aerosol
inhalation. Thus the only variable to alter the desired
delivered cyclosporine dose was exposure time.
Ethanol vapor concentration has previously12 approxi-
mated 3000 to 5000 ppm during sham exposures. From
prior toxicologic studies11 (personal communication from
ITRI), this level of ethanol vapor exposure has not
resulted in toxicity or alterations in rodent pulmonary
physiology. Therefore the ethanol vapor concentration in
this study was not determined. Oxygen levels within the
chamber were continuously monitored by a MiniOX 1
analyzer (MSA Medical Products, Pittsburgh, Pa.) and
maintained at approximately 21%.
Histologic analysis. All allografts and native lungs were
divided after being harvested and were preserved in 10%
formalin solution (Fisher Scientific, Fair Lawn, N.J.). A
medial sagittal pulmonary section was embedded in par-
affin, sectioned, stained with hematoxylin and eosin, and
blindly graded by a previously reported standardized
nomenclature for lung allograft rejection.17 In brief, the
grading scale is as follows: grade 0, no cellular infiltrates;
grade 1, perivascular infiltrates of small round and trans-
formed large lymphoid cells and immunoblasts and endo-
theliolitis (endothelial cell hypertrophy and epithelioid
changes); grade 2, perivascular mononuclear infiltrates
with spread into adjacent alveolar septae and prominent
alveolar macrophages; grade 3, perivascular mononuclear
infiltrate with peribronchiolar inflammation, lymphocyte
epidermotropism, epithelial cell and alveolar pneumocyte
necrosis, diffuse interstitial pneumonitis, hyaline mem-
branes, and intraalveolar accumulation of neutrophils and
macrophages; grade 4, vascular thrombosis with massive
intraalveolar hemorrhage and infarction and diffuse inter-
stitial pneumonia with diffuse alveolar damage.
High-pressure liquid chromatography. Whole blood,
allograft, native lung, and spleen specimens were assayed
by high-pressure liquid chromatography as previously
described18 to obtain trough cyclosporine levels. The
amount of cyclosporine was quantitated with the standard
curve of the blood cyclosporine assay, and the tissue
concentration was calculated from the tissue weight and
initial sample dilution. Levels were expressed as nano-
grams per milliliter of blood and nanograms per milligram
of weighted tissue.
Reverse-transcriptase polymerase chain reaction (RT-
PCR). First-strand deoxyribonucleic acid (cDNA) was
synthesized by transcription from tissue ribonucleic acid
(RNA). Oligonucleotides, designed from published se-
quences of cytokine mRNA, were custom synthesized by
the University of Pittsburgh DNA Synthesis facility. The
RT-PCR of the cDNA was performed as previously
described.19 Amplification for the tested cytokines, in-
cluding interleukin-6 (IL-6), interleukin-10 (IL-10), inter-
feron-g (INF-g), and inducible nitric oxide synthase
(iNOS), was performed for 28 cycles on a model 480
thermal cycler (Perkin Elmer Corp., Norwalk, Conn.).
These four cytokines were chosen on the basis of previous
studies from our laboratory20 demonstrating them to be
the most informative in this model of lung allograft
rejection. PCR products were analyzed by electrophoresis
on 2% agarose in Tris boric acid ethylenediaminetetraace-
tic acid, dried on a gel dryer, visualized by ethidium
bromide staining, and quantified with a Betagen radioana-
lytic scanner (Ambis Systems Inc., San Diego, Calif.). The
results obtained for each cytokine, in counts per minute,
were normalized to cyclophilin and expressed as the mean
ratio of mRNA to cyclophilin.
Statistical analysis. Differences in grade of rejection
and blood and tissue concentrations between experimen-
tal groups was made by one-way analysis of variance with
a post hoc analysis by the Bonferroni t test. The Student’s
unpaired t test was used to determine differences among
experimental groups (aerosol vs systemic cyclosporine).
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Exact p values are reported, with a p value of , 0.05
considered significant. Data are expressed as mean 6
standard deviation.
Results
Rejection grade and histology. Control recipients
(group A), receiving no immunosuppression, exhib-
ited severe destructive grade 4 rejection by POD 6
(Table I). Grossly, the allografts were edematous
and necrotic. Histologically, there was obliteration
of the alveoli with necrotic debris, interstitial de-
struction, and vascular thrombosis (Fig. 1, A). The
control group differed in rejection grade from all
treatment groups (Table I).
Aerosol cyclosporine recipients (groups B, C, and
D) exhibited a dose-dependent improvement in
rejection grade from 2.5 6 0.5 to 1.0 6 0 (Table I).
The most effective aerosol cyclosporine dose was in
group D recipients (3 mg/kg per day), with these
animals displaying mild grade 1 rejection by POD 6.
Grossly, the allografts in these recipients appeared
entirely normal; microscopically, there appeared to
be minimal cellular interstitial infiltration with
perivascular inflammation. The pulmonary architec-
ture and alveolar integrity were preserved (Fig. 1, B).
Recipients of systemic cyclosporine (groups E, F,
G, and H) also displayed a dose-dependent response
in rejection grade from 2.5 6 0.4 to 1.0 6 0.8 (Table
I). The most effective cyclosporine dose (15 mg/kg
per day) also resulted in a mild grade 1 rejection by
POD 6. Grossly and microscopically, group H (Fig.
1, D) and group D recipient allografts appeared
similar. It is notable that an equivalent incremental
decrease in rejection grade (2.5 to 1.0) required a
disproportionate increase in systemic cyclosporine
dosing compared with aerosol cyclosporine.
High-pressure liquid chromatography: Blood and
tissue cyclosporine levels. All treated animals had
measurable cyclosporine levels in blood, allograft,
and spleen. The most effective aerosol cyclosporine
dose (3 mg/kg per day) achieved cyclosporine levels
in the blood and tissue that were significantly differ-
ent from those measured in groups B and C (blood
levels, D vs B, p 5 0.000725; D vs C, p 5 0.004830;
tissue levels, D vs B, p 5 0.000444; D vs C, p 5
0.001547). The pulmonary/blood ratio of cyclospor-
ine was highest in the group D animals, with the best
rejection control (Table I). These animals had
trough graft concentrations of 12,349 6 8,830 ng/mg
with blood concentrations of 725 6 222 ng/ml, both
considered nontoxic by previously published phar-
macokinetic and toxicologic studies.21 In recipients
treated with aerosol cyclosporine, spleen cyclospor-
ine concentrations were significantly lower (p 5
0.006608) than allograft cyclosporine concentra-
tions.
Significant blood and tissue concentrations of
cyclosporine developed in systemically treated ani-
mals (Table I). The most effective group H recipi-
ents had blood concentrations of 3306 6 1092 ng/ml
and graft concentrations of 28,714 6 15,805 ng/mg,
both approaching toxicity if maintained over the
Table I. Cumulative data for the experimental groups, including treatment, rejection grade, and tissue
cyclosporine (CsA) levels
Group N Treatment Rejection Blood Graft Spleen
Pulmonary/
blood ratios
A 8 None 4 6 0 0 0 0
B 8 1 mg/kg aer CsA 2.5 6 0.5 160 6 80 2,564 6 1,331 1,244 6 1,504 16
C 8 2 mg/kg aer CsA 2.25 6 0.3 265 6 99 4,409 6 1,496 2,369 6 800 16.6
D 8 3 mg/kg aer CsA 1 6 0 725 6 222 (1)* 12,349 6 8,830 (2)† 6,043 6 3,934 (3) 17
E 8 2 mg/kg IM CsA 2.5 6 0.4 400 6 72 5,861 6 3,001 4,324 6 1,981 14.7
F 8 5 mg/kg IM CsA 2 6 0.4 1,074 6 284 15,482 6 6,508 11,820 6 5,234 14.4
G 8 10 mg/kg IM CsA 1.5 6 0.6 2,433 6 340 18,512 6 11,978 15,264 6 8,139 7.6
H 8 15 mg/kg IM CsA 1 6 0.8 3,306 6 1,092 (4) 28,714 6 15,805 (5) 25,708 6 12,286 (6) 8.7
aer, Aerosol; IM, intramuscular; ANOVA, analysis of variance
(1) Group D , groups B (p 5 0.000725) or C (p 5 0.004830), ANOVA and Bonferroni t test.
(2) Group D , groups B (p 5 0.000444) or C (p 5 0.001547), ANOVA and Bonferroni t test.
(3) Group D , groups B (p 5 0.009428) or C (p 5 0.006217), ANOVA and Bonferroni t test.
(4) Group H , groups E (p 5 0.000023), F (p 0.000748), or G (p 5 0.003057), ANOVA and Bonferroni t test.
(5) Group H , groups E (p 5 0.000776), F (p 5 0.002512), or G (p 5 0.019365), ANOVA and Bonferroni t test.
(6) Group H , groups E (p 5 0.000042), F (p 5 0.000361), or G (p 5 0.002865), ANOVA and Bonferroni t test.
*Group D , groups H (p 5 0.000378) and F (p 5 0.004572), Student’s unpaired t test.
†Group D , group H (p 5 0.002044), but not group F (p 5 0.115180), Student’s unpaired t test.
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Fig. 1. Histologic studies of untreated animals and those treated with cyclosporine are displayed in the
four-panel micrograph at 203 magnification. A, An untreated allograft on POD 6 with grade 4 rejection.
B, An animal from group D (3 mg/kg per day) with grade 1 rejection. There is remarkable preservation of
the pulmonary architecture with intact air spaces and a mild inflammatory cellular accumulation in the
interstitium. C, An animal from group F (5 mg/kg per day) with a rejection grade of 2. There is some
destruction of the intraalveolar membranes with distortion of the normal pulmonary architecture. D,
Histologic study from a group H recipient (15 mg/kg per day) with grade 1 rejection. The overall
appearance is similar to that of the aerosol cyclosporine recipient.
The Journal of Thoracic and
Cardiovascular Surgery
January 1998
3 2 Mitruka et al.
long term. Blood (p 5 0.000023, 0.000748, and
0.003057) and graft (p 5 0.000776, 0.002512, and
0.019365) cyclosporine concentrations of group H
recipients differed significantly from those of groups
E, F, and G. In recipients treated with systemic
cyclosporine, graft and spleen concentrations were
similar (p 5 0.259888).
Group D and group H recipients revealed similar
rejection grades by POD 6. However, group H, at an
80% greater dose, exhibited blood (p 5 0.000378)
and tissue (p 5 0.002044) cyclosporine levels that
were significantly higher and a low pulmonary/blood
cyclosporine ratio. Similar tissue cyclosporine con-
centrations (p 5 0.115180) were observed between
group D and group F recipients. However, group F
exhibited grade 2 rejection, at a 40% greater dose,
and a low pulmonary/blood cyclosporine ratio. This
was reflected in their histologic studies (Fig. 1, C). It
appeared that cyclosporine concentrations in blood,
rather than graft, closely correlated with the incre-
mental rise in systemic cyclosporine dosing neces-
sary to achieve similar rejection control compared
with recipients of aerosol cyclosporine treatment.
RT-PCR: Cytokine gene expression. Evaluation
of cytokine gene expression between the control
group and groups D, F, and H (similar rejection
grade vs similar tissue levels to aerosol cyclosporine)
by RT-PCR gel electrophoresis is displayed in Fig. 2.
Analysis was carried out for IL-6, IL-10, INF-g, and
iNOS. Aerosol cyclosporine equivalently controlled
iNOS gene expression versus systemic therapy (15
mg/kg per day) but revealed 20 to 55 times greater
IL-6, IL-10, and IFN-g gene expression in the
allograft. Group D recipients showed 1.5 to 25 times
less cytokine gene expression than group F animals,
which did not have as great an impact on local
cytokine attenuation, although dramatic compared
with that of control animals. The counts per minute
for the measured cytokines on PODs 2, 4, and 6 are
displayed in Table II.
Discussion
The current success of lung transplantation is
largely attributed to the effectiveness of immuno-
suppressive therapy. However, systemic cyclospor-
ine provides inconsistent control, and acute rejec-
Fig. 2. RT-PCR semiquantitative PCR gel of cytokine and iNOS gene expression within the allograft on
POD 6. The control, aerosol (group D), and systemic (groups F and H) groups are represented. There is
equivalent attenuation of iNOS in groups D and H by POD 6, but greater control of cytokine gene
expression by group H. Group F recipients achieved less control than groups D and H.
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tion is almost universally predictable after lung
transplantation.2 Despite enhanced immunosup-
pression, a subset of patients have refractory acute
rejection, and nearly 50% of lung transplant recipi-
ents have obliterative bronchiolitis.5 Additionally,
the long-term maintenance of systemic immunosup-
pression has resulted in significant drug-related
morbidity.4 Increasing experimental evidence sug-
gests that the allograft locally modulates the cellular
immune response characteristic of acute rejection.
The initial nonspecific inflammatory process gains
the specificity of rejection in a supportive allograft
environment.22 This environment is influenced by
immunosuppressive therapy, but systemic immuno-
suppression incurs a delay in achieving adequate
graft levels that allows the destructive cascade to
begin. The local delivery of immunosuppressive
medications is a potential means to consistently
prevent acute rejection and decrease the adverse
consequences of systemic immunosuppression.
The early rejection response is characterized by a
rapid and aggressive nonspecific inflammatory cell
influx responding to the MHC class II surface
antigens displayed by passenger leukocytes of the
bronchus-associated lymphoid tissue.23 The recipi-
ent macrophages and leukocytes, responding to
foreign antigen, release a variety of proinflamma-
tory cytokines and nitric oxide. Concurrently, the
presentation of donor alloantigens to recipient an-
tigen-presenting cells results in the differentiation of
Th0 cells into Th1 (cellular) and Th2 (humoral)
subpopulations.24 IL-2, IL-4, IL-6, IL-10, and IFN-g
promote macrophage differentiation, cytotoxic T-
lymphocyte production, and the cell surface expres-
sion of MHC antigens. The macrophages and cyto-
toxic T-lymphocytes propagate the acute rejection
response by further release of cytokines and nitric
oxide.25, 26 The sponge matrix allograft model dem-
onstrated that the maturation and differentiation of
T cells could occur independently of the host in the
proper graft environment.27 Furthermore, the intra-
graft clonal expansion of donor-specific T and B
cells is significant by 1 week after transplantation24
and may be instrumental in the development of
chronic rejection. Cyclosporine suppresses T cell
growth factor gene expression by inhibiting IL-2
mRNA transcription.28, 29 Regional immunotherapy
is a logical step in obtaining high local and early
drug levels that would inhibit the expression of
allograft recognition targets, cytokine release, and
effector cell function and migration to the allo-
graft.30
Experimental models of heart, liver, and kidney
transplantation have repeatedly demonstrated the
efficacy of local immunosuppression in controlling
acute rejection. Locally perfused budesonide in a
rodent heterotopic heart transplant model7 resulted
in prolonged graft survival, high local drug concen-
trations, and minimal systemic drug absorption.
Systemic administration had no effect at the same
dose but had a similar effect when the dose was
doubled. Minimal class II MHC antigen expression
on donor cells and minimal IL-2 receptor gene
expression on graft infiltrating cells indicated that
local immunosuppression inhibited donor target
recognition molecule expression and recipient effec-
tor cell migration and communication within the
allograft.30 Infusion of intraarterial heparin, pred-
nisolone, mizorubicin, and 6-mercaptopurine9 in a
canine renal transplant model demonstrated an 80%
increase in local drug concentration and a similar
reduction in systemic drug delivery. A tenfold lower
drug concentration conferred an antirejection effect
equivalent or superior to that of intravenous therapy
with less systemic drug exposure. In another model,
controlled release by a cyclosporine-impregnated
collagen matrix when placed adjacent to the trans-
planted heart6 significantly prolonged allograft sur-
vival with negligible systemic tissue concentrations.
Others8 have used local and systemic cyclosporine
pump-based infusion therapy. In a cardiac allograft
model, this group found graft survivals of 6.8 days in
control animals, 13.6 days in systemically treated
animals, and 40.2 days in recipients of local cyclo-
Table II. RT-PCR obtained cytokine mRNA/cyclophilin on PODs 2, 4, and 6 for the various treatment groups
Untreated Aerosol (3 mg/kg) Systemic (5 mg/kg) Systemic (15 mg/kg)
POD 2 4 6 POD 2 4 6 POD 2 4 6 POD 2 4 6
IL-6 530 605 1180 215 263 133 530 260 267 128 18 7
IL-10 80 115 605 68 90 140 70 140 248 25 22 5
IFN-g 205 290 255 58 155 55 25 65 80 7 3 1
iNOS 90 330 735 0 10 8 60 120 203 3 1 7
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sporine. A similar dose given intravenously or orally
did not realize the same beneficial effect. Regardless
of the experimental model these studies have used,
cyclosporine concentration measurements have con-
sistently shown that the lung appears to have a
particular avidity for cyclosporine.
The effectiveness of aerosolized cyclosporine has
been demonstrated previously by our group in ani-
mal models. Initial studies in dogs revealed the
ability of aerosol cyclosporine to prevent or reduce
acute pulmonary rejection with high local cyclospor-
ine concentrations and low systemic drug delivery.10
Follow-up studies in the rodent model11, 12 indicated
that the local delivery of aerosol cyclosporine was
superior to the systemic route in preventing rejec-
tion with significantly lower systemic cyclosporine
delivery. Recently, a more efficient and clinically
reflective aerosol delivery system has been con-
structed, and the calculated intrapulmonary deposi-
tion of cyclosporine by aerosol inhalation in rodents
has been altered. We sought to determine the
effectiveness of aerosol cyclosporine monotherapy
in controlling acute rejection with high local levels
and low systemic drug delivery. Additionally, with
the ability of molecular techniques to measure allo-
graft cytokine activity, the effect of aerosol cyclo-
sporine on acute rejection at the molecular level
could be determined.
In this study, we convincingly demonstrate that
aerosol cyclosporine as locoregional immunother-
apy can dose dependently prevent acute rejection in
a fully allogeneic rodent lung transplant model. An
aerosol cyclosporine dose of 3 mg/kg per day re-
sulted in grade 1 rejection and was equivalent or
superior to that of systemic cyclosporine administra-
tion. An 80% greater systemic cyclosporine dose (15
mg/kg per day) also resulted in grade 1 rejection, but
at significantly higher blood and graft concentra-
tions than in the aerosol cyclosporine group. A 40%
greater systemic cyclosporine dose (5 mg/kg per
day) resulted in similar graft concentrations to the
most effective aerosol cyclosporine group, but rejec-
tion (grade 2) was incompletely controlled. Trough
tissue levels in the allograft after aerosol therapy
were lower than with systemic therapy, yet rejection
was better controlled. The superior control of rejec-
tion by aerosol cyclosporine may be due in part to
the higher “peak” concentrations of cyclosporine
achieved and the higher pulmonary/blood ratios
observed in these recipients. Follow-up pharmaco-
kinetic studies of aerosol cyclosporine are war-
ranted. Additionally, the intrapulmonary distribu-
tion of aerosol cyclosporine, with its consequent
impact on rejection and inflammatory cytokine pro-
duction, may provide important information regard-
ing the potent effect of minute aerosol cyclosporine
doses on the prevention of acute rejection. Systemic
absorption of cyclosporine is low when administered
locally, probably at levels that do not significantly
influence control of rejection or cause toxicity. We
have demonstrated that aerosol cyclosporine effec-
tively controlled gene expression of proinflamma-
tory cytokines IL-6, IL-10, IFN-g, and iNOS in the
allograft. High-dose systemic cyclosporine (15
mg/kg per day) achieved better cytokine control
than aerosol cyclosporine, but at the cost of ex-
tremely high blood and tissue cyclosporine concen-
trations. A systemically administered dose (5 mg/kg
per day) with similar tissue levels did not adequately
control cytokine gene expression, which was re-
flected in a higher rejection grade.
In summary, we have demonstrated that aerosol
cyclosporine as local immunotherapy prevents acute
pulmonary rejection, achieves effective allograft cy-
closporine concentrations with low systemic drug
delivery, and locally attenuates the production of
the proinflammatory cytokines known to be instru-
mental in the acute rejection response. If the utility
and efficacy of aerosol cyclosporine in preventing
chronic rejection can be demonstrated, the impact
on clinical lung transplantation would be significant.
We gratefully acknowledge the expert technical assis-
tance of Natalya Subbotina, MS (high-pressure liquid
chromatography assays), Edward B. Barr, MS, and Bruce
A. Muggenberg, DVM (ITRI, aerosol equipment).
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Discussion
Dr. Nasser K. Altorki (New York, N.Y.). It seems that
the aerosolized cyclosporine did not quite eradicate the
cytokines as effectively as the 15 mg dose of systemic
steroids. Did you evaluate some potential side effects in
the treated animals with the higher dose of systemic versus
the aerosolized component?
Dr. Mitruka. Thank you, Dr. Altorki. There were no
directly observed side effects in either group of treatment
recipients in this short-term model of lung transplanta-
tion. The literature is replete with information regarding
systemically administered cyclosporine with chronically
maintained blood levels in the 3000 ng/mg range. After 45
to 60 days of persistently elevated levels, nephrotoxicity
and hepatotoxicity are observed. No data are currently
available regarding the toxicity of long-term aerosolized
cyclosporine. We did not actually measure renal or he-
patic levels of cyclosporine, despite the elevated tissue and
blood levels, because we did not expect to observe signif-
icant toxicity in this 6-day acute rejection mode.
Dr. Chi-Ming Wei (Baltimore, Md.). Do you have data
for endothelial nitric oxide synthase (eNOS) expression,
nitrate level, and cyclic guanosine monophosphate con-
centration?
Dr. Mitruka. Thank you, Dr. Wei, for your insightful
question. There are many forms of NOS, including induc-
ible and constitutive. The inflammatory process that char-
acterizes early acute rejection is mediated predominantly
by the inducible isoform of NOS. We therefore measured
iNOS by the PCR as a means to determine the amount of
nitric oxide being produced after treatment of the recip-
ient with cyclosporine. We did not measure direct nitric
oxide metabolites such as nitrate or nitrite levels, nor did
we specifically measure eNOS or cyclic guanosine mono-
phosphate. We have been interested in measuring endo-
thelial cell activation by immunohistochemistry for the
intercellular and endothelial cell leukocyte adhesion mol-
ecules, and those studies are planned for the near future.
Dr. William A. Cook (North Andover, Mass.). A number
of years ago when we were doing some work with micro-
circulatory studies of acute rejection and observing what
was going on inside the vessels, a lot of what we saw was
apparent red cell clumping around white cells. These
clumps were plugging up the smaller capillaries. It would
seem to me that an aerosol treatment would not get to
affect that particular part of the hyperacute rejection
syndrome. Would it be interesting for you to add another
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cohort to your experimental study, which would give some
cyclosporine systemically and some with aerosol and see if
your total achieved effect is not better?
Dr. Mitruka. Thank you, Dr. Cook, for that interesting
suggestion. We have considered combined therapy with
aerosol and systemic cyclosporine in this model but have
not explored it further at this early juncture, merely
because we wanted to determine the isolated effect of
aerosol monotherapy in controlling rejection.
Early deposition studies performed by Dr. Dowling, and
by our collaborators in Albuquerque, have actually indicated
that aerosol cyclosporine is deposited in all lung fields and in
the proximal and distal airways of the rodent after lung
transplantation. Although you are certainly correct that the
early changes of acute rejection consist of vascular occlusion
and direct parenchymal damage, based on our cytokine
analysis, aerosol cyclosporine actually seems to diminish the
early activation of the inflammatory cells that are directly
responsible for the immediate damage.
Dr. Robert D. Dowling (Louisville, Ky.). You described
a 3 mg aerosolized dose. Was that the dose that you
aerosolized or the dose that the animals received?
Dr. Mitruka. The 3 mg/kg per day dose of aerosolized
cyclosporine represented the target dose that was aero-
solized and delivered to the animals. The actual intrapul-
monary deposition of cyclosporine was calculated on the
basis of a consideration of the animal’s weight, minute
ventilation, and the anticipated efficiency of deposition.
Rodents weighing 250 gm received 0.75 actual milligrams
of cyclosporine per day per exposure.
Dr. Dowling. I think that is an important point. This
difference in the dose received between the group treated
with systemic cyclosporine and the group treated with
aerosolized cyclosporine is even more apparent when you
look at actually how much of the aerosolized drug the
animals received versus how much was aerosolized but not
inhaled.
Dr. Mitruka. That is an excellent point that may not
be readily apparent. The equivalently effective systemic
dose to result in a rejection grade of 1 required 15
mg/kg per day or 3.75 mg per animal per day of systemic
cyclosporine, which was 80% higher than the aerosol
cyclosporine dose of 3 mg/kg per day or 0.75 mg per
animal per day.
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